In Response to Letter to Editor JAT-26-4812-Interpretation of Breath Cannabinoids and Implications for Impairment.

This study presents a standardized and quantitatively reproducible method for the simultaneous analysis of Δ9-THC, Δ8-THC, cannabidiol (CBD), and cannabinol (CBN) in exhaled breath aerosols using the Cannabix Technologies Breath Collection Unit (BCU). Breath is a non-invasive matrix with a short detection window for Δ9-THC, making it suitable for assessing recent cannabis use. The method provides a foundation for studying cannabinoid pharmacokinetics and pharmacodynamics in breath. It is not intended to measure impairment but rather to provide an objective analytical framework for quantifying cannabinoids as regulatory and scientific interest evolves. Analytical validation followed established forensic standards. Chromatographic resolution met accepted criteria (Rs = 0.9), as recommended in NLCP guidelines for workplace drug testing. Method selectivity was confirmed using over 400 authentic samples, demonstrating reliable differentiation between Δ8-THC and Δ9-THC. Overall, this method establishes a robust platform for breath-based cannabinoid analysis.